Lu 29-252: Difference between revisions
Content deleted Content added
→(top): Made sure they knew Tags: Manual revert Reverted Mobile edit Mobile web edit |
m Reverted 1 edit by Bobthethirdzzz (talk) to last revision by Sigma440 Tags: Twinkle Undo Reverted Mobile edit Mobile web edit Advanced mobile edit |
||
| Line 64: | Line 64: | ||
}} |
}} |
||
'''Lu 29-252''' is a [[binding selectivity|selective]] [[sigma receptor|sigma]] [[sigma-2 receptor|σ<sub>2</sub> receptor]] [[ligand (biochemistry)|ligand]] which was under development for the treatment of [[anxiety disorder]]s but was never marketed.<ref name="AdisInsight">{{cite web | title=LU 29252 | work = AdisInsight | publisher = Springer Nature Switzerland AG | date=23 May 1995 | url=https://adisinsight.springer.com/drugs/800003571 | access-date=22 October 2024}}</ref><ref name="TTD">{{cite web | title = LU-29252 | work = Therapeutic Target Database (TTD) | url=https://idrblab.net/ttd/data/drug/details/d0t8hu | access-date=22 October 2024 | id = D0T8HU }}</ref><ref name="GronierDebonnel1999">{{cite journal | vauthors = Gronier B, Debonnel G | title = Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems | journal = European Journal of Pharmacology | volume = 368 | issue = 2–3 | pages = 183–196 | date = March 1999 | pmid = 10193654 | doi = 10.1016/s0014-2999(99)00025-4 }}</ref><ref name="AbaimovKovalev2011">{{cite journal | vauthors = Abaimov DA, Kovalev GI | title=Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease | journal=Neurochemical Journal | publisher=Pleiades Publishing Ltd | volume=5 | issue=2 | year=2011 | issn=1819-7124 | doi=10.1134/s1819712411010028 | pages=83–91}}</ref><ref name="RousseauxGreene2016">{{cite journal | vauthors = Rousseaux CG, Greene SF | title = Sigma receptors [σRs]: biology in normal and diseased states | journal = Journal of Receptor and Signal Transduction Research | volume = 36 | issue = 4 | pages = 327–388 | date = August 2016 | pmid = 26056947 | pmc = 4906365 | doi = 10.3109/10799893.2015.1015737 }}</ref> It reached the [[preclinical research|preclinical stage of development]] prior to the discontinuation of its development. |
'''Lu 29-252''' is a [[binding selectivity|selective]] [[sigma receptor|sigma]] [[sigma-2 receptor|σ<sub>2</sub> receptor]] [[ligand (biochemistry)|ligand]] which was under development for the treatment of [[anxiety disorder]]s but was never marketed.<ref name="AdisInsight">{{cite web | title=LU 29252 | work = AdisInsight | publisher = Springer Nature Switzerland AG | date=23 May 1995 | url=https://adisinsight.springer.com/drugs/800003571 | access-date=22 October 2024}}</ref><ref name="TTD">{{cite web | title = LU-29252 | work = Therapeutic Target Database (TTD) | url=https://idrblab.net/ttd/data/drug/details/d0t8hu | access-date=22 October 2024 | id = D0T8HU }}</ref><ref name="GronierDebonnel1999">{{cite journal | vauthors = Gronier B, Debonnel G | title = Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems | journal = European Journal of Pharmacology | volume = 368 | issue = 2–3 | pages = 183–196 | date = March 1999 | pmid = 10193654 | doi = 10.1016/s0014-2999(99)00025-4 }}</ref><ref name="AbaimovKovalev2011">{{cite journal | vauthors = Abaimov DA, Kovalev GI | title=Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease | journal=Neurochemical Journal | publisher=Pleiades Publishing Ltd | volume=5 | issue=2 | year=2011 | issn=1819-7124 | doi=10.1134/s1819712411010028 | pages=83–91}}</ref><ref name="RousseauxGreene2016">{{cite journal | vauthors = Rousseaux CG, Greene SF | title = Sigma receptors [σRs]: biology in normal and diseased states | journal = Journal of Receptor and Signal Transduction Research | volume = 36 | issue = 4 | pages = 327–388 | date = August 2016 | pmid = 26056947 | pmc = 4906365 | doi = 10.3109/10799893.2015.1015737 }}</ref> It reached the [[preclinical research|preclinical stage of development]] prior to the discontinuation of its development.<ref name="AdisInsight" /> The drug was under development by [[Lundbeck]].<ref name="AdisInsight" /> |
||
== References == |
== References == |
||
Revision as of 21:05, 21 June 2026
 | |
| Clinical data | |
|---|---|
| Other names | Lu-29-252; LU-29252; LU29252; Lu 29–252 |
| Drug class | Sigma σ2 receptor ligand |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| PubChem SID | |
| Chemical and physical data | |
| Formula | C28H36N2O2 |
| Molar mass | 432.608 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Lu 29-252 is a selective sigma σ2 receptor ligand which was under development for the treatment of anxiety disorders but was never marketed.[1][2][3][4][5] It reached the preclinical stage of development prior to the discontinuation of its development.[1] The drug was under development by Lundbeck.[1]
References
- ^ a b c "LU 29252". AdisInsight. Springer Nature Switzerland AG. 23 May 1995. Retrieved 22 October 2024.
- ^ "LU-29252". Therapeutic Target Database (TTD). D0T8HU. Retrieved 22 October 2024.
- ^ Gronier B, Debonnel G (March 1999). "Involvement of sigma receptors in the modulation of the glutamatergic/NMDA neurotransmission in the dopaminergic systems". European Journal of Pharmacology. 368 (2–3): 183–196. doi:10.1016/s0014-2999(99)00025-4. PMID 10193654.
- ^ Abaimov DA, Kovalev GI (2011). "Sigma receptors as a pharmacological target for neuroprotectors. New horizons of pharmacotherapy of Parkinson disease". Neurochemical Journal. 5 (2). Pleiades Publishing Ltd: 83–91. doi:10.1134/s1819712411010028. ISSN 1819-7124.
- ^ Rousseaux CG, Greene SF (August 2016). "Sigma receptors [σRs]: biology in normal and diseased states". Journal of Receptor and Signal Transduction Research. 36 (4): 327–388. doi:10.3109/10799893.2015.1015737. PMC 4906365. PMID 26056947.
 | This article about an anxiolytic is a stub. You can help Wikipedia by adding missing information. |